Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Changes in the staging system for HPV+ cancer patients

Hisham Mehanna • 29 Nov 2018
ESMO 2018
General

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS(ORL-HNS), of the University of Birmingham, Birmingham, UK, speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, discussing recent changes to the old staging system for HPV-positive cancer patients. Changes to clinical staging and pathological staging are explained.

More from Hisham Mehanna

2:27
Improving patient selection for surgical candidates with head and neck cancer
Hisham Mehanna • 28 Sep 2019
3:58
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
Hisham Mehanna • 30 Sep 2019
2:12
The omega score: an emerging biomarker for risk determination
Hisham Mehanna • 29 Nov 2018
1:23
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT
Hisham Mehanna • 29 Nov 2018

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals